SCHEMBL5736397

SCHEMBL5736397

CCCCc1ccc(-c2cncc(C=O)c2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARB P10826 9/20 0.45
ALDH1A1 P00352 4/20 0.40
MAPT P10636 3/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
RARA P10276 2/20 0.40
MTOR P42345 1/20 0.40
PTGS2 P35354 1/20 0.39
AKR1C2 P52895 1/20 0.39
AKR1C1 Q04828 1/20 0.39
HSD11B1 P28845 1/20 0.39
GPR84 Q9NQS5 1/20 0.39
EP300 Q09472 1/20 0.39
KAT2A Q92830 1/20 0.39
KAT2B Q92831 1/20 0.39
CTRC Q99895 1/20 0.39
RAB9A P51151 3/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
HPGD P15428 2/20 0.38
HSD17B10 Q99714 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL416529 0.81 RARB (0.56) RARBALDH1A1MAPTMEN1KMT2A
SCHEMBL5734087 0.79 TRIM24 (0.50) RARBALDH1A1MAPTMEN1KMT2A
SCHEMBL29066265 0.78 MKNK1 (0.49) PTGS2
SCHEMBL27546443 0.78 CYP2A6 (0.49) PTGS2
SCHEMBL30530576 0.78 HRH3 (0.52) ALDH1A1PTGS2
SCHEMBL29066287 0.78 HRH3 (0.52) ALDH1A1PTGS2
SCHEMBL2922984 0.76 TDP1 (0.46) ALDH1A1PTGS2GPR84RAB9ASMN1; SMN2
SCHEMBL4716336 0.76 RARB (0.57) RARBALDH1A1MAPTMEN1KMT2A
SCHEMBL2321467 0.76 HDAC1 (0.55) ALDH1A1MAPTMEN1KMT2APTGS2
SCHEMBL16572248 0.76 RARB (0.57) RARBALDH1A1MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1244446-B1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2006-11-02 EP disclosed
US-6858630-B2 Naphthimidazole derivatives and their use as thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION (US) 2005-02-22 US disclosed
US-20030083361-A1 Naphtho(1,2-d)imidazole derivatives; treating thrombocytopenia SMITHKLINE BEECHAM CORPORATION 2003-05-01 US disclosed
EP-1244446-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2003-01-08 EP disclosed
EP-1244446-A1 THROMBOPOIETIN MIMETICS SmithKline Beecham Corporation (US) 2002-10-02 EP disclosed
WO-2001039773-A1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2001-06-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030083361-A1 Naphtho(1,2-d)imidazole derivatives; treating thrombocytopenia MPL, THPO, TPO RARB 4166/4885ALDH1A1 2193/4885MAPT 4381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.